Printer Friendly

IMRE CLINICAL TRIAL CONFIRMS RESULTS OF INDEPENDENT RHEUMATOID ARTHRITIS STUDY

 SEATTLE, Oct. 14 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE) announced today that it will seek permission from the U.S. Food and Drug Administration (FDA) to expand its multi-center study for the treatment of rheumatoid arthritis patients with the PROSORBA(R) column. Results of IMRE's clinical trial confirmed the report of one year ago by Dr. Craig Wiesenhutter (Coeur d'Alene Arthritis Clinic) and Dr. Juergan Bertram (North Idaho Cancer Center) of an independent study treating rheumatoid arthritis patients with the PROSORBA column.
 A year ago, IMRE Corporation initiated an FDA-approved, multi-center study at three major U.S. medical institutions to confirm the results of the independent study. Based on the recommendation of the clinicians who participated in IMRE's multi-center study and the collection of supporting data, IMRE intends to ask the FDA for permission to expand its multi-center clinical trial in rheumatoid arthritis. The company stated that it was presently designing the expanded study and anticipates applying to the FDA for permission to conduct the study in the near future.
 IMRE Corporation is a medical products company that is the leader in the field of immunoadsorption treatments. The company's first product, the PROSORBA column, has been approved by the Food and Drug Administration and is marketed and sold for the treatment of immune thrombocytopenic purpura (ITP), an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases, and certain cancers.
 -0- 10/14/93
 /CONTACT: Lois Yoshida of IMRE Corporation, 206-298-9400/
 (IMRE)


CO: IMRE Corporation ST: Washington IN: MTC SU:

LD -- NY003 -- 2013 10/14/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 14, 1993
Words:264
Previous Article:HOUGHTON MIFFLIN COMPANY ANNOUNCES PLAN TO SPIN OFF SOFTWARE DIVISION
Next Article:CHECKERS DRIVE-IN RESTAURANTS, INC. LITIGATION FILED AGAINST CHECKERS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters